Nyxoah SA
No SEC Form 4 filings for $NYXH in the last 30 days.
See all $NYXH insider activity →Nyxoah SA reported 12-month ACCCESS data showing a 74.3% median AHI reduction with Genio in CCC OSA patients. The company filed a PMA supplement with the FDA to expand Genio’s indication to CCC patients, with no serious adverse events reported. According to Nyxoah, a positive FDA decision could be a significant commercial catalyst.
Nyxoah SA (NYXH) shares dropped 2% after-hours after CFO John Landry announced his departure in 2026. Loïc Moreau will serve as interim CFO. The company reaffirmed its 2026 guidance: €36M-€40M revenue, 60%-62% gross margin, and €99M-€102M operating expenses.
Nyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NYXH (Nyxoah SA). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent NYXH coverage spans earnings, financial news and technology.
Positive clinical-to-regulatory update that could broaden Genio’s label and improve commercial addressable market if FDA accepts/approves the supplement.
Leadership change may cause short‑term volatility; guidance unchanged suggests limited immediate impact.
Nyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.
Positive trial results may boost investor confidence and drive short-term price appreciation.
Wider loss despite sharp revenue growth suggests margin pressure and potential cash-burn risk, likely keeping valuation and financing expectations in focus.
AlphAI scores every news story that mentions NYXH with an AI model for sentiment and relevance, and aggregates insider trades from Nyxoah SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nyxoah SA reported 12-month ACCCESS data showing a 74.3% median AHI reduction with Genio in CCC OSA patients. The company filed a PMA supplement with the FDA to expand Genio’s indication to CCC patients, with no serious adverse events reported. According to Nyxoah, a positive FDA decision could be a significant commercial catalyst.
3 min readNyxoah SA (NYXH) shares dropped 2% after-hours after CFO John Landry announced his departure in 2026. Loïc Moreau will serve as interim CFO. The company reaffirmed its 2026 guidance: €36M-€40M revenue, 60%-62% gross margin, and €99M-€102M operating expenses.
2 min readNyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.
2 min readNyxoah SA (NYXH) reported positive results from its ACCCESS trial for the Genio system in treating sleep apnea with Complete Concentric Collapse (CCC). The study met primary efficacy and safety endpoints, with 77.2% AHI responder rate and 87.7% ODI responder rate. NYXH shares rose 29.14% in overnight trading.
2 min readNyxoah S.A. (NYXH) reported a wider Q2 GAAP loss of EUR32.96 million, or EUR0.578 per share, versus a EUR20.61 million loss and EUR0.551 per share a year earlier. Revenue increased 473.1% to EUR7.68 million from EUR1.34 million, according to the company.
2 min readNyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium –
2 min readNyxoah SA (NYXH) reported Q2 2026 net revenue of €7.7 million, up from €1.3 million a year earlier, with U.S. net revenue €5.2 million, 22% higher sequentially. First-half 2026 net revenue was €14.0 million. The company secured $110 million financing, had €97.8 million cash at June 30, and guided FY2026 revenue €36-40 million and gross margin 60-62%.
6 min readNyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.
4 min readNyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.
6 min readNyxoah SA (Euronext Brussels/Nasdaq: NYXH) said it received EU transparency notifications. Orin Hirchman-controlled entities acquired voting securities, raising voting rights to 14,534,880 (14.55%) vs a 10% threshold, effective June 10, 2026. Resmed Inc. reported a passive downward crossing below 3%, holding 1,943,828 voting rights (1.95%).
3 min read
